Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform NEW YORK, August 13, 2020 — CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases […]
Angus Liu of FierceBiotech reports on new research on Miro1 and implications for Parkinson’s disease.
Science Daily reports on a recent publication by researchers at Stanford, Mayo Clinic, and Atomwise.
Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.
Mark Terry of BioSpace reports on Atomwise’s three new joint ventures.
Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.